The NASDAQ-listed company will use proceeds for working capital after pricing 9M shares and 17M pre-funded warrants.
Haoxi Health Technology secured $6.5M through a registered direct offering, selling 9M Class A ordinary shares and nearly 17M pre-funded warrants at $0.25 each. The pre-funded warrants carry a nominal $0.0026 exercise price and are convertible into 10.355 shares each.
The offering follows a pricing structure tied to the share price, with proceeds earmarked for general corporate purposes and working capital. The transaction is set to close around May 12, 2026.
Shares of Haoxi Health rose 3.11% following the announcement.